Symphogen-Biovitrum Phase II Clinical Trial Initiated
Symphogen Enters into strategic collaboration with Genentech for antibody thera-peutics
Biovitrum and Symphogen Initiates a Second Clinical study with a Novel Treatment of Hemolytic Diseases
Symphogen issued patent covering Symplex™ technology for antibody discovery
Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
Biovitrum og Symphogen har færdiggjort succesfyldt fase I klinisk forsøg med et rekombinant polyklonalt antistof
Symphogen IBC Sym003 Press release
Symphogen A/S kåret som Danmarks bedste biotekvirksomhed
Symphogen A/S awarded Best Danish Biotech Company 2007
Symphogen appoints Ian Nicholson to Board of Directors
Symphogen styrker bestyrelse
Symphogen Granted European Patent Covering Use of Polyclonal Antibodies for Allergy Indications
Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation
Symphogen og Biovitrum indleder kliniske studier af ny type lægemiddel
Symphogen receives 5 Million Euro investment from Gilde Healthcare Partners
Symphogen og Meiji indgår samarbejde
Symphogen and Meiji Kaisha enter agreement for recombinant polyclonal antibody product
Symphogen A/S styrker klinisk udvikling
Symphogen appoints Christian Meyer Vice President of Clinical Development and Dr. Henrik Rasmussen to Medical Advisory Board
Symphogen A/S får patent på Sympress™ teknologi til produktion af rekombinante polyklonale antistoffer
Symphogen Issued Patent Covering Sympress™ Technology for Manufacturing Rekombinant Polyclonal Antibodies
Symphogen to evaluate AttSite™ Recombinase for development of manufacturing cell lines
Symphogen appoints Dr Søren Bregenholt Vice President of Project Management
Symphoen udnævner Søren Bregenholt til Vice President of Project Management
Biovitrum and Symphogen Enter Co-development and Commercialization Agreement for Recombinant Polyclonal Antibodies for the treatment of certain blood disorders
Symphogen på vej mod nyt lægemiddel
Kapitaltilførsel på 154 millioner kroner til Symphogen til videre udvikling af rekombinante polyklonale antistoffer
Symphogen A/S and Cambridge Antibody Technology Sign Patent Licensing Agreement
Symphogens Success in Manufacturing Consistent Batches of Polyclonal Antibodies for Clinical Trials Attracts New USD 25 Million Investment
Media InquiriesKari Watson MacDougall Biomedical Communications 508-647-0209 kari@macbiocom.com
News Archive
Calendar
